Table 1.
Summary of clinical trials using MUC16-mesothelin (MSLN) and FN - α5β1 integrin targeted agents.
| Target | Agent | Type of clinical trial | Patient population | Enrollment | Status | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|---|
| HGF | Rilotumumab | Phase II | Patients with recurrent or persistent ovarian cancer | 31 | Completed | NCT01039207 |
| MUC16 | Oregovomab | Phase II | Patients with ovarian cancer (FIGO Stage III or IV) | 102 | Terminated | NCT00034372 |
| Oregovomab | Phase III | Patients with ovarian cancer (FIGO Stage III or IV) | 354 | Terminated | NCT00050375 | |
| Oregovomab | Phase II | Patients with ovarian, fallopian tube, or peritoneal cancer | 102 | No known | NCT00004064 | |
| Oregovomab | Phase II | Patients with residual disease from stage III or stage IV ovarian epithelial, fallopian tube, or peritoneal cancer following surgery and chemotherapy | 400 | No known | NCT00003634 | |
| Oregovomab +Carboplatin + Paclitaxel |
Phase II | Patients with advanced ovarian cancer | 97 | Completed | NCT01616303 | |
| Oregovomab +Bevacizumab +Paclitaxel +Carboplatin |
Phase I/II | Patients with BRCA wild type platinum sensitive recurrent ovarian cancer | 54 | Recruiting | NCT04938583 | |
| Oregovomab +Nivolumab | Phase I/II | Patients with epithelial cancer of ovarian, tubal or peritoneal origin | 13 | Terminated | NCT03100006 | |
| Oregovomab +Poly ICLC |
Phase I | Patients with CA125-associated, advanced ovarian cancer (FIGO Stage III/IV) | 10 | Terminated | NCT03162562 | |
| Oregovomab +Paclitaxel + Carboplatin +Placebo |
Phase III | Patients with advanced epithelial ovarian cancer following optimal debulking surgery | 602 | Recruiting | NCT04498117 | |
| Oregovomab + Nivolumab + Chemotherapy |
Phase I/II | Patients with epithelial cancer of ovarian, tubal or peritoneal origin | 31 | Recruiting | NCT04620954 | |
| Oregovomab +PLD |
Phase II | patients with PARP inhibitor-resistant ovarian cancer | 28 | Recruiting | NCT05407584 | |
| Oregovomab +Niraparib |
Phase II | Patients with platinum sensitive recurrent ovarian cancer. | 10 | Recruiting | NCT05335993 | |
| DMUC5754A | Phase I | Patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer | 77 | Completed | NCT01335958 | |
| REGN4018 | Phase I/II | Patients with recurrent ovarian cancer | 554 | Recruiting | NCT03564340 | |
| REGN4018 | Phase I/II | Patients with recurrent ovarian cancer | 326 | Recruiting | NCT04590326 | |
| mesothelin (MSLN) | MORAb-009 | Phase I | Patients with mesothelin-positive cancers: ovarian, pancreatic, mesothelioma, non-small cell lung cancer. | 24 | Completed | NCT00325494 |
| MORAb-009 | Phase I | Patients with mesothelin-positive cancers: ovarian, pancreatic, mesothelioma, non-small cell lung cancer. | 6 | Completed | NCT01521325 | |
| MORAb-009 | Early phase I | Patients with mesothelin-positive cancers: ovarian, pancreatic, mesothelioma, non-small cell lung cancer. | 7 | Terminated | NCT01413451 | |
| Anetumab Ravtansine +Pegylated Liposomal Doxorubicin |
Phase I | Patients with ovarian cancer | 65 | Completed | NCT 02751918 | |
| Anetumab Ravtansine + Bevacizumab + Paclitaxe |
Phase I | Patients with refractory ovarian, fallopian tube, or primary peritoneal cancer | 96 | Active, not recruiting | NCT03587311 | |
| LCAR-M23 (CAR-T cell) | Phase I | Patients with relapsed and refractory epithelial ovarian cancer | 34 | No known | NCT04562298 | |
| αPD1-MSLN-CAR T cells | Early phase I | Patients with MSLN-positive advanced solid tumors: ovarian cancer, cholangiocarcinoma, colorectal cancer | 10 | Recruiting | NCT04503980 | |
| α5β1 integrin | Volociximab +Liposomal Doxorubicin |
Phase I/II | Patients with advanced epithelial ovarian cancer or primary peritoneal cancer relapsed after prior therapy with Plat/Taxane-based chemo | 138 | Completed | NCT00635193 |
| Volociximab | Phase II | Patients with platinum-resistant, advanced epithelial ovarian or primary peritoneal cancer | 16 | Terminated | NCT00516841 |